Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma

Authors :: Hans Gertje
Saravanan Thiyagarajan
Biswanath Majumder
K.s. Sabitha
Basava U. Shanthappa
Mark Lawson
Abhishek Basu
Govind Babu Kanakasetty
Pradip K. Majumder
Padhma Radhakrishnan
Manjusha Biswas
Munisha Smalley
Pradeep Kumar Kar
K Jay G Ray
Nandini Pal Basak
Aaron Goldman
Source :: Journal of Clinical Oncology. 36:e18042-e18042
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e18042Background: PD-1 inhibition has shown promise in second-line, platinum (Pt) resistant HNSCC (e.g. KEYNOTE-055). To improve the outcome of PD-1 blockade, clinical trials are testing immunother...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Pembrolizumab
medicine.disease
Head and neck squamous-cell carcinoma
Blockade
Clinical trial
Internal medicine
medicine
business
Ex vivo

Full Text Access

Tools